Unknown PHASE2 INTERVENTIONAL 1-arm NCT01325896

Maintenance Treatment of Multiple Myeloma (MM) After Autologous Peripheral Blood Transplant (PBSCT) Using Polyethylene Glycol alpha2B Interpheron (PEG-INTRON)

Sponsor: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

Updated 5 times since 2017 Last updated: Mar 30, 2011 Started: Sep 30, 2002 Primary completion: Mar 31, 2012 Completion: Mar 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Multiple Mieloma, this trial is ongoing. The trial is conducted by Fundación de Investigación Biomédica - Hospital Universitario de La Princesa and has accumulated 5 data snapshots since 2002. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE2

First recorded

Sep 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
Haematology Service,

Data source: Fundación de Investigación Biomédica - Hospital Universitario de La Princesa

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madrid, Spain